Importation
Maine’s Medicaid program analysis shows the truth: importing medicine from Canada would cost more, not less.
In an analysis of 50 prospective drugs, Maine’s Medicaid program found that it would lose nearly a million additional dollars ($927,983.28, to be exact) importing these drugs from Canada. How can this be? For many reasons, Canada is not the land of cheap drugs people think it is.
[...]Statement on Litigation Challenging Legality of Administration’s Final Rule Permitting State-Sponsored Drug Importation From Canada
Today, PhRMA, The Partnership for Safe Medicines and Council for Affordable Health Coverage initiated litigation in the U.S. District Court for the District of Columbia challenging action by HHS and FDA permitting pharmacists and wholesalers, pursuant to state-sponsored programs, to import certain prescription drugs from Canada into the United States without drug manufacturers’ authorization or oversight.
[...]Why We’re Suing the Federal Government to Preserve Public Health and Safety
Until September 24, 2020, every head of the Department of Health and Human Services, supported by every head of the U.S. Food and Drug Administration, since 2003 had refused to certify the safety of bulk drug importation from Canada.[1] This was not a partisan issue. Both Republican and Democratic administration public health leaders opposed it.…
[...]Counterfeit Medicine News for the Week of November 16, 2020
In PSM’s round-up this week: Government authorities take legal action against COVID scammers; an insurance broker (allegedly) decided to open his own unlicensed pharmacy; ongoing counterfeit medicine news, and more.
[...]An Analysis Of New Mexico’s Draft Canadian Drug Importation Plan
The state of New Mexico released a draft of its Canadian drug importation plan. PSM analyzed the plan, paying particular attention to concerns pharmacists might have about how drug importation might affect their patients and business…
[...]“Reducing costs requires more than all of this non–value-added activity,” Expert Says
In this October 23, 2020 editorial, which was published in the The American Journal of Managed Care, Michael Abrams explains why drug importation will not save patients money. Abrams is the co-founder and managing partner of Numerof & Associates.
[...]Counterfeit Medicine: Crime and Policy, October 20, 2020
A summary briefing of 2020’s major cases, worrying trends and a deep dive into drug supply chain policy issues.
[...]“…barriers will delay or prevent drug importation,” say regulatory experts
In this analysis, which was published in Lexology on October 13, 2020, three global regulatory experts examine barriers to drug importation.
[...]Colorado Health and Human Services Committee hearing on SB 119 – February 13, 2020
On February 13, 2020 the Colorado Senate’s Health and Human Services Committee held a hearing during which a member of the committee asked where the $810,000 to implement drug importation has gone, and what the progress is. His questions, which are directed to head of the agency and the lead importation pharmacist, begin at 6:56.…
[...]Wyoming’s Dept. of Health Recommends The State Not Attempt A Drug Importation Program
Wyoming is one of many states that decided to examine if importing drugs would provide significant savings to its citizens. In a hearing in August and a report released today, they took a critical look at the issue and the Department of Health recommends that the state not pursue the idea for several key reasons…
[...]